LENZ Therapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 3, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 3, 2026
LENZ$4.10-4.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities | ||
| Net loss | $(104,375) | $(46,231) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 330 | 180 |
| Loss on impairment of operating right-of-use assets and related property and equipment | — | 82 |
| Loss on impairment of property and equipment | 253 | — |
| Accretion of discounts and amortization of premiums on marketable securities, net | (486) | (2,801) |
| Gain on long-term investments | — | (204) |
| Write-off of nonsalable inventory | 556 | — |
| Share-based compensation expense | 12,925 | 8,869 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable, net | (584) | — |
| Inventory | (1,651) | (949) |
| Prepaid expenses and other current assets | 1,879 | (1,103) |
| Accounts payable | 1,350 | 66 |
| Accrued liabilities | (4,770) | 5,946 |
| Operating lease liabilities, net | (54) | — |
| Other assets | 21 | — |
| Net cash used in operating activities | (94,606) | (36,145) |
| Cash flows from investing activities | ||
| Purchases of marketable securities | (32,534) | (147,691) |
| Proceeds from maturities of marketable securities | 132,139 | 162,622 |
| Purchases of property and equipment | (34) | (789) |
| Net cash provided by investing activities | 99,571 | 14,142 |
| Cash flows from financing activities | ||
| Proceeds from issuance of common stock through at-the-market offerings, net of issuance costs | — | 26,067 |
| Proceeds from exercises of stock options | 14 | 838 |
| Proceeds from issuance of common stock under employee stock purchase plan | 395 | 225 |
| Net cash provided by financing activities | 409 | 27,130 |
| Net increase in cash, cash equivalents and restricted cash | 5,374 | 5,127 |
| Cash, cash equivalents and restricted cash, beginning of the period | 25,179 | 20,272 |
| Cash and cash equivalents, end of the period | $30,553 | $25,399 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.